Literature DB >> 6981516

Differential actions of calcium antagonists on calcium binding to cardiac sarcolemma.

D C Pang, N Sperelakis.   

Abstract

The action of four calcium antagonistic drugs, including verapamil, bepridil, nifedipine, and diltiazem, on calcium binding to cardiac sarcolemma from guniea pig was tested. It was found that verapamil (10(-6) to 10(-5) M) inhibited calcium binding to a great extent. Bepridil at the same concentrations was less potent than verapamil in the depression of calcium binding. Nifedipine and diltiazem did not affect sarcolemmal calcium binding. The differential action of the calcium antagonistic drugs was discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981516     DOI: 10.1016/0014-2999(82)90105-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Nifedipine impairs neutrophil respiratory burst by a mechanism other than calcium channel blockade.

Authors:  K Nalini; K I Andrabi; N K Ganguly; P L Wahi
Journal:  Mol Cell Biochem       Date:  1990-03-05       Impact factor: 3.396

2.  Comparative effects of bepridil, its quaternary derivative CERM 11888 and verapamil on caffeine-induced contracture in ferret hearts.

Authors:  J Leboeuf; C Leoty; J C Lamar; R Massingham
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

3.  Functional interactions of calcium-antagonists in K+-depolarized smooth muscle.

Authors:  M Spedding
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

4.  Effects of calcium antagonistic drugs on the electrical activity of rabbit sino-atrial node.

Authors:  P A Molyvdas; N Sperelakis
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

5.  Myocardial infarction: is bepridil, a new calcium antagonist, able to improve the course of the acute phase?

Authors:  D Flammang; M Waynberger; R Paillet; C Pruvot; G Cosson; A Chassing
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.